The herein used FGFR inhibitors TKI258 and BGJ398 are already applied in clinical trials of other tumor entities, such as FGFR3 mutated bladder cancer or squamous cell lung cancer with FGFR1 amplification (e.g. NCT01004224 or NCT01831726). This evidence concerns the gene FGFR1 and urinary bladder cancer.